Ipilimumab in patients with cancer and the management of dermatologic adverse events
Ipilimumab in patients with cancer and the management of dermatologic adverse events is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Ipilimumab in patients with cancer and the management of dermatologic adverse events have?
Ipilimumab in patients with cancer and the management of dermatologic adverse events has 184 citations in the OpenAlex counts ScholarIQ stores.
When was Ipilimumab in patients with cancer and the management of dermatologic adverse events published?
Ipilimumab in patients with cancer and the management of dermatologic adverse events has 2014 year in the ScholarIQ index.
What is the open-access status of Ipilimumab in patients with cancer and the management of dermatologic adverse events?
Ipilimumab in patients with cancer and the management of dermatologic adverse events has closed oa status in the ScholarIQ index.
What is the DOI of Ipilimumab in patients with cancer and the management of dermatologic adverse events?
The DOI for Ipilimumab in patients with cancer and the management of dermatologic adverse events is on the source record.
What is the PMID of Ipilimumab in patients with cancer and the management of dermatologic adverse events?
The PMID for Ipilimumab in patients with cancer and the management of dermatologic adverse events is on the source record.
What is the OpenAlex record for Ipilimumab in patients with cancer and the management of dermatologic adverse events?
The OpenAlex for Ipilimumab in patients with cancer and the management of dermatologic adverse events is on the source record.